1. Surani MA: Imprinting and the Initiation of Gene Silencing in the Germ Line. Cell. 1998;93(3):309-12.
2. Lucifero D, Mann MR, Bartolomei MS, et al: Gene-specific timing and epigenetic memory in oocyte imprinting. Hum Mol Genet. 2004;13(8):839-49.
3. Obata Y, Kono T: Maternal primary imprinting is established at a specific time for each gene throughout oocyte growth. J Biol Chem. 2002;277(7):5285-9.
4. Peters J: The role of genomic imprinting in biology and disease: an expanding view. Nat Rev Genet. 2014;15(8):517-30.
5. Nelissen EC, van Montfoort AP, Dumoulin JC, et al: Epigenetics and the placenta. Hum Reprod Update. 2011;17(3):397-417.
6. Surani MA, Barton SC, Norris ML: Development of reconstituted mouse eggs suggests imprinting of the genome during gametogenesis. Nature. 1984;308(5959):548-50.
7. McGrath J, Solter D: Completion of mouse embryogenesis requires both the maternal and paternal genomes. Cell. 1984;37(1):179-83.
8. Wallace DC, Surti U, Adams CW, et al: Complete moles have paternal chromosomes but maternal mitochondrial DNA. Hum Genet. 1982;61(2):145-7.
9. Linder D, McCaw BK, Hecht F: Parthenogenic origin of benign ovarian teratomas. N Engl J Med. 1975;292(2):63-6.
10. Zink F, Magnusdottir DN, Magnusson OT, et al: Insights into imprinting from parent-of-origin phased methylomes and transcriptomes. Nat Genet. 2018;50(11):1542-52.
11. Smith FM, Garfield AS, Ward A: Regulation of growth and metabolism by imprinted genes. Cytogenet Genome Res. 2006;113(1-4):279-91.
12. Kaneko-Ishino T, Ishino F: Retrotransposon silencing by DNA methylation contributed to the evolution of placentation and genomic imprinting in mammals. Dev Growth Differ. 2010;52(6):533-43.
13. Babak T, DeVeale B, Tsang EK, et al: Genetic conflict reflected in tissue-specific maps of genomic imprinting in human and mouse. Nat Genet. 2015;47(5):544-9.
14. Okae H, Hiura H, Nishida Y, et al: Re-investigation and RNA sequencing-based identification of genes with placenta-specific imprinted expression. Hum Mol Genet. 2012;21(3):548-58.
15. Okae H, Matoba S, Nagashima T, et al: RNA sequencing-based identification of aberrant imprinting in cloned mice. Hum Mol Genet. 2014;23(4):992-1001.
16. Hamada H, Okae H, Toh H, et al: Allele-Specific Methylome and Transcriptome Analysis Reveals Widespread Imprinting in the Human Placenta. Am J Hum Genet. 2016;99(5):1045-58.
17. Lurain JR: Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol. 2010;203(6):531-9.
18. Shih I-M: Gestational trophoblastic neoplasia—pathogenesis and potential therapeutic targets. The Lancet Oncology. 2007;8(7):642-50.
19. Kajii T, Ohama K: Androgenetic origin of hydatidiform mole. Nature. 1977;268(5621):633-4.
20. Wake N, Takagi N, Sasaki M: Androgenesis as a cause of hydatidiform mole. J Natl Cancer Inst. 1978;60(1):51-7.
21. Sanchez-Delgado M, Martin-Trujillo A, Tayama C, et al: Absence of Maternal Methylation in Biparental Hydatidiform Moles from Women with NLRP7 Maternal-Effect Mutations Reveals Widespread Placenta-Specific Imprinting. PLoS Genet. 2015;11(11):e1005644.
22. Sebire NJ, May PC, Kaur B, et al: Abnormal villous morphology mimicking a hydatidiform mole associated with paternal trisomy of chromosomes 3,7,8 and unipaternal disomy of chromosome 11. Diagn Pathol. 2016;11:20.
23. DeScipio C, Haley L, Beierl K, et al: Diandric triploid hydatidiform mole with loss of maternal chromosome 11. Am J Surg Pathol. 2011;35(10):1586-91.
24. Yamamoto E, Niimi K, Kiyono T, et al: Establishment and characterization of cell lines derived from complete hydatidiform mole. Int J Mol Med. 2017;40(3):614-22.
25. Okae H, Toh H, Sato T, et al: Derivation of Human Trophoblast Stem Cells. Cell Stem Cell. 2018;22(1):50-63 e6.
26. Trapnell C, Roberts A, Goff L, et al: Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7(3):562-78.
27. Kawai Y, Mimori T, Kojima K, et al: Japonica array: improved genotype imputation by designing a population-specific SNP array with 1070 Japanese individuals. J Hum Genet. 2015;60(10):581-7.
28. Miura F, Enomoto Y, Dairiki R, et al: Amplification-free whole-genome bisulfite sequencing by post-bisulfite adaptor tagging. Nucleic Acids Res. 2012;40(17):e136.
29. Miura F, Ito T: Highly sensitive targeted methylome sequencing by post-bisulfite adaptor tagging. DNA Res. 2015;22(1):13-8.
30. Krueger F, Andrews SR: Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics. 2011;27(11):1571-2.
31. Mali P, Yang L, Esvelt KM, et al: RNA-Guided Human Genome Engineering via Cas9. Science. 2013;339(6121):823-6.
32. Montague TG, Cruz JM, Gagnon JA, et al: CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. Nucleic Acids Res. 2014;42(Web Server issue):W401-7.
33. Lee CQ, Gardner L, Turco M, et al: What Is Trophoblast? A Combination of Criteria Define Human First-Trimester Trophoblast. Stem Cell Reports. 2016;6(2):257-72.
34. Hemberger M, Udayashankar R, Tesar P, et al: ELF5-enforced transcriptional networks define an epigenetically regulated trophoblast stem cell compartment in the human placenta. Hum Mol Genet. 2010;19(12):2456-67.
35. Schroeder DI, Blair JD, Lott P, et al: The human placenta methylome. Proc Natl Acad Sci U S A. 2013;110(15):6037-42.
36. Court F, Tayama C, Romanelli V, et al: Genome-wide parent-of-origin DNA methylation analysis reveals the intricacies of human imprinting and suggests a germline methylation-independent mechanism of establishment. Genome Res. 2014;24(4):554-69.
37. Choufani S, Shuman C, Weksberg R: Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet. 2010;154C(3):343-54.
38. Eggermann T, Binder G, Brioude F, et al: CDKN1C mutations: two sides of the same coin. Trends Mol Med. 2014;20(11):614-22.
39. Fock V, Plessl K, Fuchs R, et al: Trophoblast subtype-specific EGFR/ERBB4 expression correlates with cell cycle progression and hyperplasia in complete hydatidiform moles. Hum Reprod. 2015;30(4):789-99.
40. Abercrombie M, Heaysman JE: Observations on the social behaviour of cells in tissue culture. I. Speed of movement of chick heart fibroblasts in relation to their mutual contacts. Exp Cell Res. 1953;5(1):111-31.
41. Constancia M, Hemberger M, Hughes J, et al: Placental-specific IGF-II is a major modulator of placental and fetal growth. Nature. 2002;417(6892):945-8.
42. Gabory A, Ripoche MA, Yoshimizu T, et al: The H19 gene: regulation and function of a non-coding RNA. Cytogenet Genome Res. 2006;113(1-4):188-93.
43. . !!! INVALID CITATION !!! , 41).
44. Steinberg KM, Schneider VA, Graves-Lindsay TA, et al: Single haplotype assembly of the human genome from a hydatidiform mole. Genome Res. 2014;24(12):2066-76.
45. Ullah Z, Kohn MJ, Yagi R, et al: Differentiation of trophoblast stem cells into giant cells is triggered by p57/Kip2 inhibition of CDK1 activity. Genes Dev. 2008;22(21):3024-36.
46. Yan Y, Frisen J, Lee MH, et al: Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev. 1997;11(8):973-83.
47. Sebire NJ, Rees HC, Peston D, et al: p57(KIP2) immunohistochemical staining of gestational trophoblastic tumours does not identify the type of the causative pregnancy. Histopathology. 2004;45(2):135-41.
48. Mayor R, Carmona-Fontaine C: Keeping in touch with contact inhibition of locomotion. Trends Cell Biol. 2010;20(6):319-28.
49. McClatchey AI, Yap AS: Contact inhibition (of proliferation) redux. Curr Opin Cell Biol. 2012;24(5):685-94.
50. Abercrombie M: Contact inhibition and malignancy. Nature. 1979;281(5729):259-62.
51. Pateras IS, Apostolopoulou K, Niforou K, et al: p57KIP2: "Kip"ing the cell under control. Mol Cancer Res. 2009;7(12):1902-19.
52. Zhang P, Liégeois NJ, Wong C, et al: Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith–Wiedemann syndrome. Nature. 1997;387(6629):151-8.
53. Kanayama N, Takahashi K, Matsuura T, et al: Deficiency in p57Kip2 expression induces preeclampsia-like symptoms in mice. Mol Hum Reprod. 2002;8(12):1129-35.
54. Tunster SJ, Van de Pette M, John RM: Fetal overgrowth in the Cdkn1c mouse model of Beckwith-Wiedemann syndrome. Disease Models & Mechanisms. 2011;4(6):814-21.
55. Romanelli V, Belinchon A, Campos-Barros A, et al: CDKN1C mutations in HELLP/preeclamptic mothers of Beckwith-Wiedemann Syndrome (BWS) patients. Placenta. 2009;30(6):551-4.
56. Korgun ET, Celik-Ozenci C, Acar N, et al: Location of cell cycle regulators cyclin B1, cyclin A, PCNA, Ki67 and cell cycle inhibitors p21, p27 and p57 in human first trimester placenta and deciduas. Histochem Cell Biol. 2006;125(6):615-24.
57. Gumbiner BM, Kim NG: The Hippo-YAP signaling pathway and contact inhibition of growth. J Cell Sci. 2014;127(Pt 4):709-17.
58. Motti ML, Califano D, Baldassarre G, et al: Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis. 2005;26(6):1021-34.
59. Ohashi K, Fujiwara S, Mizuno K: Roles of the cytoskeleton, cell adhesion and rho signalling in mechanosensing and mechanotransduction. J Biochem. 2017;161(3):245-54.
60. Lopez-Abad M, Iglesias-Platas I, Monk D: Epigenetic Characterization of CDKN1C in Placenta Samples from Non-syndromic Intrauterine Growth Restriction. Front Genet. 2016;7:62.
61. Monk D, Arnaud P, Apostolidou S, et al: Limited evolutionary conservation of imprinting in the human placenta. Proc Natl Acad Sci U S A. 2006;103(17):6623-8.
62. Martin DA, Sutton GP, Ulbright TM, et al: DNA content as a prognostic index in gestational trophoblastic neoplasia. Gynecol Oncol. 1989;34(3):383-8.
63. Nishiya I, Moriya S, Yamashita K, et al: Cytophotometric DNA determination of trophoblastic neoplasia. Gynecol Oncol. 1977;5(2):103-8.
64. Bjornsson HT, Brown LJ, Fallin MD, et al: Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors. J Natl Cancer Inst. 2007;99(16):1270-3.
65. Buiting K, Kanber D, Horsthemke B, et al: Imprinting of RB1 (the new kid on the block). Briefings in Functional Genomics. 2010;9(4):347-53.
66. Lee MH, Reynisdottir I, Massague J: Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 1995;9(6):639-49.
67. Matsuoka S, Edwards MC, Bai C, et al: p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 1995;9(6):650-62.
68. Chilosi M, Piazzola E, Lestani M, et al: Differential expression of p57kip2, a maternally imprinted cdk inhibitor, in normal human placenta and gestational trophoblastic disease. Lab Invest. 1998;78(3):269-76.
69. Weksberg R, Shuman C, Smith AC: Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet. 2005;137C(1):12-23.
70. Scelfo RA, Schwienbacher C, Veronese A, et al: Loss of methylation at chromosome 11p15.5 is common in human adult tumors. Oncogene. 2002;21(16):2564-72.
論文の公開元へ
